新型氟萘啶酮LB20304的抗菌活性及抗菌谱
Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.
作者信息
Cormican M G, Jones R N
机构信息
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA.
出版信息
Antimicrob Agents Chemother. 1997 Jan;41(1):204-11. doi: 10.1128/AAC.41.1.204.
Abstract
Compound LB20304 is a fluoronaphthyridone carboxylic acid with a novel pyrrolidine substituent. This drug was compared with ciprofloxacin, levofloxacin, ofloxacin, and trovafloxacin against over 800 pathogens, most from blood stream infections, by National Committee for Clinical Laboratory Standards reference methods. LB20304 was the most active agent against gram-positive species including strains observed to be resistant to other fluoroquinolones and glycopeptides. The potency of LB20304 (MIC50, 0.03 micrograms/ml) against the Enterobacteriaceae was exceeded only by that of ciprofloxacin (0.015 micrograms/ml). It has limited activity against gram-negative anaerobes.
摘要
化合物LB20304是一种带有新型吡咯烷取代基的氟萘啶酮羧酸。通过美国国家临床实验室标准委员会的参考方法，将该药物与环丙沙星、左氧氟沙星、氧氟沙星和曲伐沙星针对800多种病原体进行了比较，其中大多数病原体来自血流感染。LB20304是针对革兰氏阳性菌最具活性的药物，包括对其他氟喹诺酮类药物和糖肽类药物耐药的菌株。LB20304对肠杆菌科细菌的效力（MIC50为0.03微克/毫升）仅次于环丙沙星（0.015微克/毫升）。它对革兰氏阴性厌氧菌的活性有限。
相似文献
1
Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.新型氟萘啶酮LB20304的抗菌活性及抗菌谱
Antimicrob Agents Chemother. 1997 Jan;41(1):204-11. doi: 10.1128/AAC.41.1.204.
2
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.新型氟萘啶酮LB20304的体外和体内评价
Antimicrob Agents Chemother. 1996 Jun;40(6):1564-8. doi: 10.1128/AAC.40.6.1564.
3
Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.吉米沙星与氟喹诺酮类药物对全球监测研究中近期欧洲临床分离株的体外比较效力
Eur J Clin Microbiol Infect Dis. 2001 Nov;20(11):814-9. doi: 10.1007/s100960100604.
4
Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.北美一项监测研究中吉米沙星、环丙沙星、左氧氟沙星和氧氟沙星的体外活性比较
Diagn Microbiol Infect Dis. 2001 May-Jun;40(1-2):51-7. doi: 10.1016/s0732-8893(01)00241-3.
5
Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens.吉米沙星对革兰氏阳性和革兰氏阴性厌氧性病原体的体外活性综述。
J Antimicrob Chemother. 2000 Apr;45 Suppl 1:55-65. doi: 10.1093/jac/45.suppl_3.55.
6
Comparative in vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolates.包括吉米沙星在内的五种喹诺酮类抗生素对临床分离株的体外活性比较
Clin Microbiol Infect. 2001 Sep;7(9):499-503. doi: 10.1046/j.1198-743x.2001.00297.x.
7
8
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.环丙沙星、左氧氟沙星、洛美沙星、氧氟沙星、培氟沙星、司帕沙星和曲伐沙星对呼吸道感染革兰氏阳性和革兰氏阴性病原体的体外活性。
J Antimicrob Chemother. 1997 Sep;40(3):427-31. doi: 10.1093/jac/40.3.427.
9
Antimicrobial activity of LB20304, a fluoronaphthyridone, tested against anaerobic bacteria.氟萘啶酮LB20304对厌氧菌的抗菌活性。
J Antimicrob Chemother. 1997 Oct;40(4):605-7. doi: 10.1093/jac/40.4.605.
10
Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.阿根廷吉米沙星对革兰氏阳性和革兰氏阴性临床分离株的体外活性比较
Diagn Microbiol Infect Dis. 2001 Aug;40(4):187-92. doi: 10.1016/s0732-8893(01)00271-1.
引用本文的文献
1
A Validated Reverse Phase-Ultra-Performance Liquid Chromatography Method for the Determination of Gemifloxacin Mesylate in Bulk and its Pharmaceutical Preparation.一种验证过的反相超高效液相色谱法用于测定原料药及制剂中的甲磺酸吉米沙星
Turk J Pharm Sci. 2019 Mar;16(1):8-13. doi: 10.4274/tjps.04934. Epub 2018 Dec 31.
2
The new fluoroquinolones: A critical review.新型氟喹诺酮类药物：批判性综述。
Can J Infect Dis. 1999 May;10(3):207-38. doi: 10.1155/1999/378394.
3
Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin.P-糖蛋白和 MRP2 对吉米沙星细胞内转运的差异作用。
Int J Pharm. 2011 Nov 25;420(1):26-33. doi: 10.1016/j.ijpharm.2011.08.009. Epub 2011 Aug 16.
4
Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.丙磺舒对吉米沙星肾小管分泌的竞争性抑制作用。
Antimicrob Agents Chemother. 2009 Sep;53(9):3902-7. doi: 10.1128/AAC.01200-08. Epub 2009 Jun 29.
5
Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus.金黄色葡萄球菌中吉米沙星对拓扑异构酶的靶向作用及耐药性
Antimicrob Agents Chemother. 2003 Jan;47(1):274-82. doi: 10.1128/AAC.47.1.274-282.2003.
6
Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.吉米沙星和其他氟喹诺酮介导的野生型和耐喹诺酮肺炎链球菌II型拓扑异构酶形成可裂解复合物
Antimicrob Agents Chemother. 2002 Feb;46(2):413-9. doi: 10.1128/AAC.46.2.413-419.2002.
7
A critical review of the fluoroquinolones: focus on respiratory infections.氟喹诺酮类药物的批判性综述：聚焦于呼吸道感染
Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002.
8
Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria.吉米沙星、其他喹诺酮类药物及非喹诺酮类抗菌药物对专性厌氧菌的体外比较活性
Antimicrob Agents Chemother. 2001 Jun;45(6):1896-9. doi: 10.1128/AAC.45.6.1896-1899.2001.
9
Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers.健康志愿者口服吉米沙星的多剂量药代动力学及耐受性研究。
Antimicrob Agents Chemother. 2001 Feb;45(2):540-5. doi: 10.1128/AAC.45.2.540-545.2001.
10
Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.吉米沙星强大的抗肺炎球菌活性与对回旋酶和拓扑异构酶IV的双重靶向作用、在体内对回旋酶的靶点偏好以及在体外增强可裂解复合物的稳定性有关。
Antimicrob Agents Chemother. 2000 Nov;44(11):3112-7. doi: 10.1128/AAC.44.11.3112-3117.2000.
本文引用的文献
1
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.新型氟萘啶酮LB20304的体外和体内评价
Antimicrob Agents Chemother. 1996 Jun;40(6):1564-8. doi: 10.1128/AAC.40.6.1564.
2
Hospital-acquired infections: diseases with increasingly limited therapies.医院获得性感染：治疗方法日益有限的疾病。
Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2420-7. doi: 10.1073/pnas.91.7.2420.
3
The in-vitro activity of a new highly active quinolone, DU-6859a.新型高效喹诺酮DU-6859a的体外活性
J Antimicrob Chemother. 1993 Nov;32(5):757-63. doi: 10.1093/jac/32.5.757.
4
In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.新型7-(3-氮杂双环[3.1.0]己基)萘啶酮抗菌剂CP-99,219的体外活性
Diagn Microbiol Infect Dis. 1994 Aug;19(4):235-43. doi: 10.1016/0732-8893(94)90037-x.
5
Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.美国众多医疗中心重要病原菌的流行情况及注射用药物的抗菌活性，I. 关于新出现耐药性威胁的研究：真实的还是感知到的？氟喹诺酮耐药性监测组
Diagn Microbiol Infect Dis. 1994 Aug;19(4):203-15. doi: 10.1016/0732-8893(94)90033-7.
6
Pneumococcal resistance to antibiotics.肺炎球菌对抗生素的耐药性。
Clin Microbiol Rev. 1990 Apr;3(2):171-96. doi: 10.1128/CMR.3.2.171.
Zotero 插件